Co-founder and patent co-author at Biotts, with a PhD in Pharmacy from the Medical University of Wrocław. A seasoned pharmaceutical technologist with over two decades of experience, specializing in the design of drug active ingredient nanocarriers, transdermal systems, and sterile, non-oral drug formulations. Renowned for contributions to numerous domestic and international scientific publications. At Biotts, excels in creating proprietary formulations and patents for innovative solutions.

During his tenure leading a clinical research site, Barry became frustrated with the manual methods and inefficiencies of clinical trial startup management and the capture, analysis and reporting of key trial performance metrics. He looked for a better solution, but couldn’t find one, so along with two key managers they developed Devana Solutions.

Today, Barry is President of Devana Solutions, guiding the growth and expansion of the leading and most innovative software platforms for the clinical trials industry. Barry is a successful entrepreneur who has started and successfully grown a number of businesses over his career and been actively involved in the healthcare space for well over 12 years.

Alex Guth is a Managing Director and Partner in LEK Consulting’s Boston office and a member of the Life Sciences practice. He supports clients throughout the life sciences industry, including biopharma, manufacturing and academic partners. Alex advises clients across a range of strategic needs, including therapeutic area strategy, portfolio prioritization, due diligence, and opportunity forecasting and valuation. Prior to joining LEK, Alex had over 15 years of experience in biological research. He holds a bachelor’s degree with highest departmental honors in biology and a PhD in virology, both from Harvard University.

Robert has over 20 years of experience in the medical device, biotech and pharmaceutical industries. He oversaw development and launch of over 10 different products while at Boston Scientific and Medtronic. He worked as Global Project Manager for Genentech, focused on biologics for the treatment of HER2+ breast cancer, including Perjeta, Herceptin and Kadcyla, where he oversaw the APHINITY and KATHERINE clinical trials. Robert holds a graduate degree in Industrial Engineering from the University of Costa Rica and an MBA from Harvard Business School. He currently serves as Senior Vice President of Finance and Operations at Portal Instruments.

Olga Kubassova, PhD is the founder and president of Image Analysis Group. With a strong foundation in mathematics, Dr Kubassova and IAG’s team are passionately committed to accelerating drug development and improving chances of clinical trials to succeed. Her expertise is reflected in a proven track record of driving operational excellence and fostering innovation across complex global clinical trials and business ecosystems. She is an internationally recognized scientist and speaker, focusing her efforts on helping biotech and pharma companies in leveraging the power of data, AI, and digital technologies to refine clinical trial design, execution, and data analysis. Her expertise and publications encompass many therapeutic areas, including oncology, immunology, gastroenterology, and neurosciences. Her current focus is on building impactful collaborations that will shape the future of clinical development and offer innovative solutions to longstanding challenges.

Petr Jordan, PhD is the CTO and a founding member of Onc.AI, leading technology development, scientific collaborations, and intellectual property strategy. Dr Jordan has deep expertise in medical imaging, machine learning, oncology, and medical physics. Previously, he was a Senior Staff Data Scientist at Varian Medical Systems, focusing on machine learning for radiation therapy, including treatment planning and image guidance. Before that, he was the Imaging Research Manager at Accuray, developing algorithms for CyberKnife and TomoTherapy systems. Dr Jordan holds a PhD in Medical Engineering and Medical Physics from the Harvard-MIT HST program, an MS from Harvard University, and a BS in Computer Engineering from Lipscomb University. He also completed medical school coursework and clinical training at Harvard Medical School. He is an inventor on 34 granted and 2 pending US patents.

Foluso Agboola, MBBS, MPH is the VP of Research at ICER. She is responsible for conducting rigorous analyses and critical appraisals of published medical evidence, managing the broader HTA process on reviews, as well as managing the work of members of the evidence synthesis team at ICER. Ms Agboola’s expertise is in the application of principles of evidence synthesis in healthcare and public health decision-making. Prior to joining ICER in 2016, Ms Agboola worked at Mass General Brigham Center for Drug Policy, where she developed economic evaluations to accompany rigorous reviews of clinical evidence, assessed the potential cost and budgetary impact of a wide range of clinical interventions, performed clinical forecasting, and developed pharmacoeconomic models. Prior to that, she worked at the Harvard T.H. Chan School of Public Health on designing evaluation research and the application of measurement methods to assess public health and healthcare system preparedness. Dr Agboola has authored several peer-reviewed publications, conference presentations, and educational materials.

Dr Agboola earned her medical degree from the University of Ilorin, Nigeria, and her Master of Public Health degree in Quantitative Methods from Harvard University. In her spare time, Dr Agboola enjoys going on a bike ride or hiking with her family.